NCT04200339|Completed
Adolescent SCreening To Help Eliminate Misuse
ASC-THEM
Loading search results
ASC-THEM
Sponsor study identifier
Secondary identifiers
NIH
observational
810
1 country
1
Study Start
July 21, 2020
Actual (reported)Primary Completion
February 25, 2022
Actual (reported)Study Completion
February 25, 2022
Actual (reported)The specific aim of this study is to evaluate the performance of three substance use screening instruments (S2BI, BSTAD, and TAPS Tool) against a criterion standard of Diagnostic Statistical Manual - 5 (DSM-5) substance use disorder (SUD) diagnoses in an adolescent population.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 25, 2022
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 12, 2019
Actual (reported)December 16, 2019
Actual (reported)July 21, 2020
Actual (reported)February 25, 2022
Actual (reported)February 25, 2022
Actual (reported)SUD assessment evaluation for performance
The focus of this study is to evaluate the performance of each tool (S2BI, BSTAD, and TAPS Tool) in identifying substance use and substance use disorders at previously identified cut points for alcohol, marijuana and tobacco/nicotine for each tool. The properties that will be evaluated include sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+) and negative likelihood ratio (LR-)
single visit
SUD assessment evaluation for criterion measures
We will examine each substance from each tool against the corresponding substance on the criterion standard measure. For example, the tobacco item on the BSTAD would be compared to the tobacco item on the WMH CIDI.
single visit
Adolescents between the ages of 12 and 17 years old (inclusive).
Recruitment and study procedures may occur either in-person or remotely. We will recruit participants to enroll in the study from participating health care sites. These will include 1) an outpatient adolescent substance use disorders program at a pediatric hospital (ASAP, Boston Children's Hospital), 2) the adolescent medicine program at a federally qualified health center (FQHC) in Boston (Martha Elliot Health Center (MEHC), Boston Children's Hospital), and 3) community-based primary care pediatrics practices that participate in the Pediatric Physicians' Organization at Children's (PPOC). The FQHC is considered a primary care sites participating in this study.
Boston Childrens Hopsital - Adolecents Substance Use and Addiction Program
Boston, Massachusetts, 02115, United States
Levy S, Minegishi M, Brogna M, Ross J, Subramaniam G, Weitzman ER. Screening for Nonmedical Use and Misuse of Prescription Medication by Adolescents. Subst Use Addctn J. 2025 Apr;46(2):357-363. doi: 10.1177/29767342241292419. Epub 2024 Dec 4.
Levy S, Minegishi M, Brogna M, Subramaniam G, McCormack J, Weiss R, Weitzman ER. Comparing the Performance of World Mental Health Composite International Diagnostic Interview Substance Abuse Module in Adolescents to Diagnoses Made by Pediatric Addiction Medicine Specialists. J Addict Med. 2024 Mar-Apr 01;18(2):205-208. doi: 10.1097/ADM.0000000000001271. Epub 2024 Jan 30.
Sharon Levy, MD, MPH
Boston Children's Hospital
810 participants (actual enrollment reported by the registry).
First Submitted
December 12, 2019
First Posted
December 16, 2019
Study Start
July 21, 2020
Actual (reported)The Substance Abuse Treatment to HIV Care II (SAT2HIV-II) Project
Contact the study team to confirm eligibility.
Primary Completion
February 25, 2022
Actual (reported)Study Completion
February 25, 2022
Actual (reported)Last Updated
March 18, 2022
Record last verified: 2022-03
This study will comply with the NIH Data Sharing Policy and Implementation Guidance(https://grants.nih.gov/grants/policy/data\_sharing/data\_sharing\_guidance.htm). Investigators will also register and report results of the trial in ClinicalTrials.gov, consistent with the requirements of the Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration (https://grants.nih.gov/policy/clinical-trials/reporting/understanding/nih-policy.htm).
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: